Literature DB >> 18771929

Specific binding capacity of beta-cyclodextrin with cis and trans enalapril: physicochemical characterization and structural studies by molecular modeling.

Ariana Zoppi1, Mario A Quevedo, Marcela R Longhi.   

Abstract

The main objective of this work was to study an inclusion complex between enalapril (ENA), and beta-cyclodextrin (beta-CD). From nuclear magnetic resonance (NMR) we determined that the complex showed a 1:1 stoichiometry, with an apparent formation constant (K(C)) of 439 and 290 M(-1) for the cis and trans isomers, respectively. The molecular modeling and NMR techniques demonstrated that the aromatic moiety of ENA was inserted into the hydrophobic cavity of beta-CD. When studying the chemical stability of ENA complexed to beta-CD, a clear stabilizing effect was observed in both the aqueous solution and solid state.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18771929     DOI: 10.1016/j.bmc.2008.08.032

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  3 in total

1.  Sulfobutyl ether(7) β-cyclodextrin (SBE(7) β-CD) carbamazepine complex: preparation, characterization, molecular modeling, and evaluation of in vivo anti-epileptic activity.

Authors:  Ankitkumar S Jain; Abhijit A Date; Raghuvir R S Pissurlenkar; Evans C Coutinho; Mangal S Nagarsenker
Journal:  AAPS PharmSciTech       Date:  2011-09-15       Impact factor: 3.246

2.  Increasing doxycycline hyclate photostability by complexation with β-cyclodextrin.

Authors:  Ana Carolina Kogawa; Ariana Zoppi; Mario Alfredo Quevedo; Hérida Regina Nunes Salgado; Marcela Raquel Longhi
Journal:  AAPS PharmSciTech       Date:  2014-06-03       Impact factor: 3.246

3.  Formulation and evaluation of cyclodextrin-based nanosponges of griseofulvin as pediatric oral liquid dosage form for enhancing bioavailability and masking bitter taste.

Authors:  Samia M Omar; Fares Ibrahim; Aliaa Ismail
Journal:  Saudi Pharm J       Date:  2020-02-03       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.